The next era of global innovation and dealmaking in China
The 2027 agenda will be centered around partnering and business development, investment and capital, Big Pharma strategy, AI and TechBio, biotech company building, and China’s evolving position within global biopharma.
China biotech 2027: Where innovation meets capital, AI meets pharma, and deals get done
Cross-border deals. New structures. The next era of China biotech partnerships.
Cross-border partnering remains at the heart of ChinaBio as China-originated licensing grows in scale and sophistication. This track moves beyond traditional out-licensing to explore new deal structures, co-development models, multi-asset and platform partnerships, NewCos, regional and global rights, and the rise of two-way dealmaking across borders.
What global pharma wants next. And what makes a deal worth doing.
With China now a major source of innovation for global pharmaceutical companies, the question has shifted from whether Big Pharma will partner in China to what it's looking for next. Hear how global pharma is sourcing innovation, what differentiates the opportunities attracting international attention, how dealmaking expectations are evolving, and what makes an asset or platform truly partnerable.
Built by AI. Financed differently. Partnered globally.
AI takes center stage in 2027, reflecting its growing impact across biotech investment, company building, and partnering. Beyond the technology itself, explore AI as a business proposition: how AI-native drug companies are being built, financed, and valued; what makes AI-derived assets attractive to global partners; and whether AI-native biotech represents a fundamentally different company-building model.
Where the money is going. And how China's biotech financing is evolving.
The investment landscape is shifting. This track examines how China's biotech financing environment is evolving and where capital is flowing next. Explore the changing role of venture and private capital, investment banking and public markets, the emergence of AI biotech as an investment category, and strategic investment and licensing income as sources of growth capital.